Wells Fargo Maintains Overweight on NovoCure, Lowers Price Target to $102
Portfolio Pulse from richadhand@benzinga.com
Wells Fargo analyst Larry Biegelsen has maintained an Overweight rating on NovoCure (NASDAQ:NVCR) but lowered the price target from $104 to $102.

July 28, 2023 | 3:50 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
NovoCure's price target has been lowered by Wells Fargo from $104 to $102, though the Overweight rating is maintained.
The lowering of the price target by Wells Fargo could potentially create a negative sentiment among investors, which might put downward pressure on the stock price. However, the maintained Overweight rating indicates that the analyst still sees the stock as a good investment, which could counterbalance the negative impact of the lowered price target.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100